Search
Pazufloxacin
go.drugbank.com/drugs/DB11774InvestigationalPazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAllicin
go.drugbank.com/drugs/DB11780InvestigationalAllicin has been used in trials studying the treatment of Follicular Lymphoma.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigationalFostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalMajor depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was ap...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersRelugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesValspodar
go.drugbank.com/drugs/DB11869InvestigationalValspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawnInfigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the tr...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalValbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates